A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
Phase of Trial: Phase II
Latest Information Update: 04 Jan 2019
At a glance
- Drugs Olaparib (Primary)
- Indications Cholangiocarcinoma; Glioblastoma; Glioma; Solid tumours
- Focus Therapeutic Use
- 28 Dec 2018 Status changed from suspended to recruiting.
- 31 Aug 2018 Biomarkers information updated
- 19 Jul 2018 Planned End Date changed from 31 Jul 2018 to 31 Jul 2019.